TY  - JOUR
AU  - Pérez-Ramírez, Cristina
AU  - Cañadas-Garre, Marisa
AU  - Alnatsha, Ahmed
AU  - Villar, Eduardo
AU  - Valdivia-Bautista, Javier
AU  - Faus-Dáder, María José
AU  - Calleja-Hernández, Miguel Ángel
PY  - 2018
DO  - 10.1038/s41397-018-0014-8
UR  - http://hdl.handle.net/10668/12357
T2  - The pharmacogenomics journal
AB  - Chemotherapy based on platinum compounds is the standard treatment for NSCLC patients with EGFR wild type, and is also used as second line in mutated EGFR patients. Nevertheless, this therapy presents poor clinical outcomes. ERCC1, ERCC2, XRCC1, MDM2,...
LA  - en
KW  - 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
KW  - Aged
KW  - Biomarkers, Tumor
KW  - Carcinoma, Non-Small-Cell Lung
KW  - DNA Repair
KW  - DNA-Binding Proteins
KW  - Endonucleases
KW  - Female
KW  - Folic Acid
KW  - Humans
KW  - Male
KW  - Methylenetetrahydrofolate Reductase (NADPH2)
KW  - Middle Aged
KW  - Pharmacogenetics
KW  - Platinum
KW  - Prognosis
KW  - Proportional Hazards Models
KW  - Proto-Oncogene Proteins c-mdm2
KW  - Reduced Folate Carrier Protein
KW  - Survival Analysis
KW  - X-ray Repair Cross Complementing Protein 1
KW  - Xeroderma Pigmentosum Group D Protein
TI  - Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients.
TY  - research article
VL  - 19
ER  -